SCS Ventures Private Equity for Biotech Scale-Up and GMP Manufacturing

SCS Ventures is investing in Biotech platforms and first-in-class candidates, including innovative mechanisms of action and drug repositioning Computational Modeling & Simulation (QSAR or CM&S Good Simulation Practice compliant) Internationalisation of Life Science companies & overall Life Sciences

SCS Ventures is the investment arm of Socosur Chem, still fully family-owned Paris-based group founded in 1990.

Built by entrepreneurs, we invest with the mindset of industrial Pharma keen to Biotech innovation, not financial engineers.

For more than a decade, we have been active in private equity, supporting founders who build transformative companies in biotech industry,

not to mention the fast-growing field of in silico Regulatory expertise.

Our differentiated strength: deep operational experience in regulated life sciences, combined with a global footprint.

What We Do Invest into

We support ambitious founders from Proof of Concept approved to GMP scale-up

by providing strategic guidance and targeted private investments (up to Series A level).

Our primary areas of focus include:

• Biotech first in class or drug repositionning 
• In-silico Toxicology (QSAR, CM&S, GSP) or NAMs
• Internationalisation of Life Science Companies

Our Mission

To leverage our multidisciplinary expertise in pharmaceutical operations, regulatory pathways, toxicology, and global expansion

to help tomorrow’s leaders navigate their most critical phases of growth.

Our hands-on, responsible investment approach is designed to create

long-term, sustainable value for the companies we support

as well as the scientific and financial ecosystems around them.

CM&S Momentum: from in silico Computational Modeling & Simulation to more successful first in class Biotech companies

Across multiple ventures, our team has guided founders through decisive strategic and operational milestones.

The lessons learned from our own entrepreneurial history from the foundation of the support we provide today.

Our Investment Philosophy

We partner with founders at their most decisive stages from Proof of Concept up to Series A providing capital, strategic insight, and hands-on involvement when it matters most.

Our approach is guided by three principles:

• Entrepreneurial Alignment
  We have founded, scaled, and exited companies ourselves.

We invest with the same discipline, urgency, and accountability we expect from our past investment partners.

• Strategic Value Creation
  We specialize in unlocking international growth, navigating complex regulatory landscapes,

while structuring robust scientific and commercial strategies.

• Long-Term Partnership
  Our objective is lasting value creation for

founders, employees, investors, and the pharmaceutical industry ecosystems we contribute to.

Sector Focus

We invest where our expertise and networks create the strongest advantage:

• Biotech platforms & drug development technologies
• Pharmaceutical or veterinary innovative mechanism of action innovation
• Computational & in-silico toxicology (NAM, QSAR, CM&S, GSP)
• Internationally cross-border science-driven companies

What We Bring Beyond Capital

We support portfolio companies through:

• Strategic guidance during critical inflection points
• Access to regulatory, scientific, and industrial networks
• International expansion and partnership development
• Operational mentoring based on real-world founder experience

To ensure full accessibility for current and prospective investors, SCS Ventures actively participates in major global investor events

and maintains a presence across the established communication and scheduling systems used by leading institutional investors.